REFERENCES
1. Wang K, Wu M, Xu J, Wu C,
Zhang B, Wang G, et al. Effects of dexmedetomidine on perioperative
stress, inflammation, and immune function: systematic review and
meta-analysis. Br J Anaesth. 2019 Dec;123(6):777–94.
2. Keating GM.
Dexmedetomidine: A Review of Its Use for Sedation in the Intensive Care
Setting. Drugs. 2015 Jul;75(10):1119–30.
3. Kaye AD, Chernobylsky DJ,
Thakur P, Siddaiah H, Kaye RJ, Eng LK, et al. Dexmedetomidine in
Enhanced Recovery After Surgery (ERAS) Protocols for Postoperative Pain.
Curr Pain Headache Rep. 2020 Apr 2;24(5):21.
4. Barends CRM, Absalom A, van
Minnen B, Vissink A, Visser A. Dexmedetomidine versus Midazolam in
Procedural Sedation. A Systematic Review of Efficacy and Safety. PLoS
One. 2017 Jan 20;12(1):e0169525.
5. Kawazoe Y, Miyamoto K,
Morimoto T, Yamamoto T, Fuke A, Hashimoto A, et al. Effect of
Dexmedetomidine on Mortality and Ventilator-Free Days in Patients
Requiring Mechanical Ventilation With Sepsis: A Randomized Clinical
Trial. JAMA. 2017 Apr 4;317(13):1321–8.
6. Barr J, Fraser GL, Puntillo
K, Ely EW, Gélinas C, Dasta JF, et al. Clinical practice guidelines for
the management of pain, agitation, and delirium in adult patients in the
intensive care unit. Crit Care Med. 2013 Jan;41(1):263–306.
7. Wang D, Hu B, Hu C, Zhu F,
Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized
Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China.
JAMA. 2020 Mar 17;323(11):1061–9.
8. Yang X, Yu Y, Xu J, Shu H,
Xia J ’an, Liu H, et al. Clinical course and outcomes of critically ill
patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered,
retrospective, observational study. Lancet Respir Med. 2020
May;8(5):475–81.
9. Richardson S, Hirsch JS,
Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting
Characteristics, Comorbidities, and Outcomes Among 5700 Patients
Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 May
26;323(20):2052–9.
10. Arulkumaran N, Brealey D,
Howell D, Singer M. Use of non-invasive ventilation for patients with
COVID-19: a cause for concern? Lancet Respir Med. 2020 Jun;8(6):e45.
11. Ostuzzi G, Gastaldon C,
Papola D, Fagiolini A, Dursun S, Taylor D, et al. Pharmacological
treatment of hyperactive delirium in people with COVID-19: rethinking
conventional approaches. Ther Adv Psychopharmacol. 2020 Jul
20;10:2045125320942703.
12. Henry BM, de Oliveira MHS,
Benoit S, Plebani M, Lippi G. Hematologic, biochemical and immune
biomarker abnormalities associated with severe illness and mortality in
coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med.
2020 Jun 25;58(7):1021–8.
13. Tjendra Y, Al Mana AF,
Espejo AP, Akgun Y, Millan NC, Gomez-Fernandez C, et al. Predicting
Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple
Biomarkers. Arch Pathol Lab Med. 2020 Dec 1;144(12):1465–74.
14. Lippi G, Mattiuzzi C,
Sanchis-Gomar F, Henry BM. Clinical and demographic characteristics of
patients dying from COVID-19 in Italy vs China. J Med Virol. 2020
Oct;92(10):1759–60.
15. Taboada M, Baluja A,
Santos LD, González I, Veiras S, Caruezo V, et al. Effectiveness of
dexmedetomidine combined with high flow nasal oxygen and long periods of
awake prone positioning in moderate or severe COVID-19 pneumonia. J Clin
Anesth. 2021 Mar 31;72:110261.
16. Stockton J, Kyle-Sidell C.
Dexmedetomidine and worsening hypoxemia in the setting of COVID-19: A
case report. Am J Emerg Med. 2020 Oct;38(10):2247.e1–2247.e2.
17. Paternoster G, Sartini C,
Pennacchio E, Lisanti F, Landoni G, Cabrini L. Awake pronation with
helmet continuous positive airway pressure for COVID-19 acute
respiratory distress syndrome patients outside the ICU: A case series.
Med Intensiva [Internet]. 2020 Sep 6; Available from:
http://dx.doi.org/10.1016/j.medin.2020.08.008
18. Zhao H, Davies R, Ma D.
Potential therapeutic value of dexmedetomidine in COVID-19 patients
admitted to ICU. Br J Anaesth. 2021 Jan;126(1):e33–5.
19. Cruz Salcedo EM, Rodriguez
L-M, Patel J, Seevaratnam AR. Use of Dexmedetomidine in Early Prone
Positioning Combined With High-Flow Nasal Cannula and Non-Invasive
Positive Pressure Ventilation in a COVID-19 Positive Patient. Cureus.
2020 Sep 13;12(9):e10430.
20. Magoon R. Dexmedetomidine
in COVID-19: probing promises with prudence! Am J Emerg Med
[Internet]. 2020 Oct 27; Available from:
http://dx.doi.org/10.1016/j.ajem.2020.10.034
21. Jain A, Lamperti M, Doyle
DJ. Dexmedetomidine: another arrow in the quiver to fight COVID-19 in
intensive care units. Br J Anaesth. 2021 Jan;126(1):e35–8.
22. Genel Koronavirüs Tablosu
[Internet]. [cited 2021 May 18]. Available from:
https://covid19.saglik.gov.tr/TR-66935/genel-koronavirus-tablosu.html
23. Duan X, Coburn M, Rossaint
R, Sanders RD, Waesberghe JV, Kowark A. Efficacy of perioperative
dexmedetomidine on postoperative delirium: systematic review and
meta-analysis with trial sequential analysis of randomised controlled
trials. Br J Anaesth. 2018 Aug;121(2):384–97.
24. Guan W-J, Liang W-H, Zhao
Y, Liang H-R, Chen Z-S, Li Y-M, et al. Comorbidity and its impact on
1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir
J [Internet]. 2020 May;55(5). Available from:
http://dx.doi.org/10.1183/13993003.00547-2020
25. Gao Y-D, Ding M, Dong X,
Zhang J-J, Kursat Azkur A, Azkur D, et al. Risk factors for severe and
critically ill COVID-19 patients: A review. Allergy. 2021
Feb;76(2):428–55.
26. Orbach H, Katz U, Sherer
Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe
administration. Clin Rev Allergy Immunol. 2005 Dec;29(3):173–84.
27. Šutová I, Chovancová Z,
Litzman J. Adverse effects of immunoglobulin therapy. Vnitr Lek. 2019
Winter;65(2):131–2.